Primary Article

Carbamazepine Therapy in Neuropsychiatric Patients

Authors: RICHARD L. BURNS, MD, PETER L. JENKINS, MRCPsych, A. DANIEL VALLINI, MD

Abstract

We reviewed the charts of 106 patients treated with carbamazepine. Age, sex, race, seizure type, seizure focus, age at onset, duration of epileptic illness, reasons for discontinuing treatment, other medications, and response to treatment of seizures, psychiatric symptoms, and behavioral symptoms were recorded. Statistical analysis was done to determine clinical factors influencing response to carbamazepine. Increasing duration, of epileptic illness leads to a decreased response to carbamazepine, which controls both seizure and behavioral symptoms effectively; concurrent medication decreases behavioral symptom control without affecting the control of the seizures. We found a strongly negative correlation between duration of seizures and improvement of psychiatric symptoms with carbamazepine therapy. We provide a clinical profile of the carbamazepine responder to guide clinicians in their use of this drug.


This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References